{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:07:04Z","timestamp":1788671224834,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals SA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40261-024-01355-1","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T10:01:40Z","timestamp":1714039300000},"page":"293-301","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Differential Utility Losses in Herpes Zoster Cases Between Vaccinated and Unvaccinated Subjects: A Meta-analysis of Three Clinical Trials"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9130-4744","authenticated-orcid":false,"given":"Nikolaos","family":"Giannelos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6183-387X","authenticated-orcid":false,"given":"Bernard","family":"Francq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7423-0111","authenticated-orcid":false,"given":"Desmond","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"issue":"6","key":"1355_CR1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jpain.2005.01.359","volume":"6","author":"G Oster","year":"2005","unstructured":"Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain. 2005;6(6):356\u201363. https:\/\/doi.org\/10.1016\/j.jpain.2005.01.359.","journal-title":"J Pain"},{"issue":"4","key":"1355_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10389-011-0481-8","volume":"20","author":"K Lukas","year":"2012","unstructured":"Lukas K, Edte A, Bertrand I. The impact of herpes zoster and post-herpetic neuralgia on quality of life: patient-reported outcomes in six European countries. J Public Health. 2012;20(4):441\u201351. https:\/\/doi.org\/10.1007\/s10389-011-0481-8.","journal-title":"J Public Health"},{"issue":"8","key":"1355_CR3","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40266-016-0389-7","volume":"33","author":"G Pickering","year":"2016","unstructured":"Pickering G, Marcoux M, Chapiro S, David L, Rat P, Michel M, et al. An algorithm for neuropathic pain management in older people. Drugs Aging. 2016;33(8):575\u201383. https:\/\/doi.org\/10.1007\/s40266-016-0389-7.","journal-title":"Drugs Aging"},{"issue":"3","key":"1355_CR4","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1086\/421942","volume":"39","author":"J Katz","year":"2004","unstructured":"Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis. 2004;39(3):342\u20138. https:\/\/doi.org\/10.1086\/421942.","journal-title":"Clin Infect Dis"},{"issue":"16","key":"1355_CR5","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1503\/cmaj.091711","volume":"182","author":"M Drolet","year":"2010","unstructured":"Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. Can Med Assoc J. 2010;182(16):1731\u20136. https:\/\/doi.org\/10.1503\/cmaj.091711.","journal-title":"Can Med Assoc J"},{"issue":"1","key":"1355_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1741-7015-8-37","volume":"8","author":"RW Johnson","year":"2010","unstructured":"Johnson RW, Bouhassira D, Kassianos G, Lepl\u00e8ge A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010;8(1):37. https:\/\/doi.org\/10.1186\/1741-7015-8-37.","journal-title":"BMC Med"},{"issue":"1","key":"1355_CR7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40121-021-00581-w","volume":"11","author":"D Van Oorschot","year":"2022","unstructured":"Van Oorschot D, McGirr A, Goulet P, Koochaki P, Pratiwadi R, Shah S, et al. A Cross-sectional concept elicitation study to understand the impact of herpes zoster on patients\u2019 health-related quality of life. Infect Dis Ther. 2022;11(1):501\u201316. https:\/\/doi.org\/10.1007\/s40121-021-00581-w.","journal-title":"Infect Dis Ther"},{"issue":"4","key":"1355_CR8","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1128\/CMR.00052-13","volume":"26","author":"AA Gershon","year":"2013","unstructured":"Gershon AA, Gershon MD. Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiol Rev. 2013;26(4):728\u201343. https:\/\/doi.org\/10.1128\/CMR.00052-13.","journal-title":"Clin Microbiol Rev"},{"issue":"10","key":"1355_CR9","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1086\/320169","volume":"32","author":"TT Yoshikawa","year":"2001","unstructured":"Yoshikawa TT, Schmader K. Herpes zoster in older adults. Clin Infect Dis. 2001;32(10):1481\u20136. https:\/\/doi.org\/10.1086\/320169.","journal-title":"Clin Infect Dis"},{"key":"1355_CR10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1186\/1471-2334-14-402","volume":"14","author":"A Gater","year":"2014","unstructured":"Gater A, Abetz-Webb L, Carroll S, Mannan A, Serpell M, Johnson R. Burden of herpes zoster in the UK: findings from the Zoster Quality Of Life (ZQOL) study. BMC Infect Dis. 2014;14:402. https:\/\/doi.org\/10.1186\/1471-2334-14-402.","journal-title":"BMC Infect Dis"},{"issue":"22","key":"1355_CR11","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","volume":"352","author":"MN Oxman","year":"2005","unstructured":"Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271\u201384. https:\/\/doi.org\/10.1056\/NEJMoa051016.","journal-title":"N Engl J Med"},{"key":"1355_CR12","unstructured":"Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster. Recommendations of the Advisory Committee on Immunization Practices (ACIP) 2008. https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr5705a1.htm. Accessed 1 Aug 2023."},{"key":"1355_CR13","unstructured":"European Medicines Agency (EMA). Zostavax. 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zostavax#overview-section. Accessed 1 Aug 2023."},{"issue":"3","key":"1355_CR14","doi-asserted-by":"publisher","first-page":"2278362","DOI":"10.1080\/21645515.2023.2278362","volume":"19","author":"A Mwakingwe-Omari","year":"2023","unstructured":"Mwakingwe-Omari A, Lecrenier N, Naficy A, Curran D, Posiuniene I. Recombinant zoster vaccine in immunocompetent and immunocompromised adults: a review of clinical studies. Hum Vaccin Immunother. 2023;19(3):2278362. https:\/\/doi.org\/10.1080\/21645515.2023.2278362.","journal-title":"Hum Vaccin Immunother"},{"issue":"22","key":"1355_CR15","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O, Chlibek R, D\u00edez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1501184.","journal-title":"N Engl J Med"},{"issue":"11","key":"1355_CR16","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, D\u00edez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1603800.","journal-title":"N Engl J Med"},{"issue":"2","key":"1355_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1001\/jama.2019.9053","volume":"322","author":"A Bastidas","year":"2019","unstructured":"Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, L\u00f3pez-Jim\u00e9nez J, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA. 2019;322(2):123\u201333. https:\/\/doi.org\/10.1001\/jama.2019.9053.","journal-title":"JAMA"},{"issue":"6","key":"1355_CR18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jpain.2004.06.001","volume":"5","author":"PM Coplan","year":"2004","unstructured":"Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain. 2004;5(6):344\u201356. https:\/\/doi.org\/10.1016\/j.jpain.2004.06.001.","journal-title":"J Pain"},{"issue":"5","key":"1355_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337\u201343. https:\/\/doi.org\/10.3109\/07853890109002087.","journal-title":"Ann Med"},{"issue":"24","key":"1355_CR20","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1097\/00007632-200012150-00008","volume":"25","author":"JE Ware Jr","year":"2000","unstructured":"Ware JE Jr. SF-36 health survey update. Spine. 2000;25(24):3130\u20139. https:\/\/doi.org\/10.1097\/00007632-200012150-00008.","journal-title":"Spine"},{"issue":"8","key":"1355_CR21","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/gerona\/gly150","volume":"74","author":"D Curran","year":"2019","unstructured":"Curran D, Oostvogels L, Heineman T, Matthews S, McElhaney J, McNeil S, et al. Quality of life impact of an adjuvanted recombinant zoster vaccine in adults aged 50 years and older. J Gerontol A. 2019;74(8):1231\u20138. https:\/\/doi.org\/10.1093\/gerona\/gly150.","journal-title":"J Gerontol A"},{"issue":"12","key":"1355_CR22","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1016\/j.bbmt.2019.07.036","volume":"25","author":"D Curran","year":"2019","unstructured":"Curran D, Matthews S, Rowley SD, Young JH, Bastidas A, Anagnostopoulos A, et al. Recombinant zoster vaccine significantly reduces the impact on quality of life caused by herpes zoster in adult autologous hematopoietic stem cell transplant recipients: a randomized placebo-controlled trial (ZOE-HSCT). Biol Blood Marrow Transplant. 2019;25(12):2474\u201381. https:\/\/doi.org\/10.1016\/j.bbmt.2019.07.036.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"1355_CR23","doi-asserted-by":"publisher","first-page":"CD008858","DOI":"10.1002\/14651858.CD008858.pub5","volume":"10","author":"GJ de Oliveira","year":"2023","unstructured":"de Oliveira GJ, Gagliardi AM, Andriolo BN, Torloni MR, Andriolo RB, Puga M, et al. Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev. 2023;10(10):CD008858. https:\/\/doi.org\/10.1002\/14651858.CD008858.pub5.","journal-title":"Cochrane Database Syst Rev"},{"key":"1355_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372: n160. https:\/\/doi.org\/10.1136\/bmj.n160.","journal-title":"BMJ"},{"issue":"10","key":"1355_CR25","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1007\/s11136-019-02248-z","volume":"28","author":"BD Rapkin","year":"2019","unstructured":"Rapkin BD, Schwartz CE. Advancing quality-of-life research by deepening our understanding of response shift: a unifying theory of appraisal. Qual Life Res. 2019;28(10):2623\u201330. https:\/\/doi.org\/10.1007\/s11136-019-02248-z.","journal-title":"Qual Life Res"},{"issue":"3","key":"1355_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1\u201348. https:\/\/doi.org\/10.18637\/jss.v036.i03.","journal-title":"J Stat Softw"},{"key":"1355_CR27","unstructured":"R Core Team. The R Project for statistical computing. 2022. https:\/\/www.r-project.org\/. Accessed 16 Mar 2023."},{"key":"1355_CR28","volume-title":"The handbook of research synthesis and meta-analysis","year":"2009","unstructured":"Cooper H, Hedges LV, Valentine JC, editors. The handbook of research synthesis and meta-analysis. 2nd ed. New York: Russell Sage Foundation; 2009.","edition":"2"},{"key":"1355_CR29","first-page":"295","volume-title":"The handbook of research synthesis and meta-analysis","author":"SW Raudenbush","year":"2009","unstructured":"Raudenbush SW. Analyzing effect sizes: random-effects models. In: Cooper H, Hedges LV, Valentine JC, editors. The handbook of research synthesis and meta-analysis. 2nd ed. New York: Russell Sage Foundation; 2009. p. 295\u2013315.","edition":"2"},{"issue":"1","key":"1355_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1164","volume":"7","author":"AA Veroniki","year":"2016","unstructured":"Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, et al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. 2016;7(1):55\u201379. https:\/\/doi.org\/10.1002\/jrsm.1164.","journal-title":"Res Synth Methods"},{"issue":"358","key":"1355_CR31","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1080\/01621459.1977.10480998","volume":"72","author":"DA Harville","year":"1977","unstructured":"Harville DA. Maximum likelihood approaches to variance component estimation and to related problems. J Am Stat Assoc. 1977;72(358):320\u201338. https:\/\/doi.org\/10.1080\/01621459.1977.10480998.","journal-title":"J Am Stat Assoc"},{"issue":"5","key":"1355_CR32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.6028\/jres.087.022","volume":"87","author":"RC Paule","year":"1982","unstructured":"Paule RC, Mandel J. Consensus values and weighting factors. J Res Natl Bur Stand (1977). 1982;87(5):377\u201385. https:\/\/doi.org\/10.6028\/jres.087.022.","journal-title":"J Res Natl Bur Stand (1977)"},{"issue":"3","key":"1355_CR33","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1088\/0026-1394\/41\/3\/004","volume":"41","author":"R Kacker","year":"2004","unstructured":"Kacker R. Combining information from interlaboratory evaluations using a random effects model. Metrologia. 2004;41(3):132. https:\/\/doi.org\/10.1088\/0026-1394\/41\/3\/004.","journal-title":"Metrologia"},{"issue":"2","key":"1355_CR34","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0378-3758(99)00098-1","volume":"83","author":"AL Rukhin","year":"2000","unstructured":"Rukhin AL, Biggerstaff BJ, Vangel MG. Restricted maximum likelihood estimation of a common mean and the Mandel\u2013Paule algorithm. J Stat Plan Inference. 2000;83(2):319\u201330. https:\/\/doi.org\/10.1016\/S0378-3758(99)00098-1.","journal-title":"J Stat Plan Inference"},{"issue":"1","key":"1355_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/jrsm.1316","volume":"10","author":"D Langan","year":"2019","unstructured":"Langan D, Higgins JPT, Jackson D, Bowden J, Veroniki AA, Kontopantelis E, et al. A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses. Res Synth Methods. 2019;10(1):83\u201398. https:\/\/doi.org\/10.1002\/jrsm.1316.","journal-title":"Res Synth Methods."},{"issue":"7414","key":"1355_CR36","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"issue":"6","key":"1355_CR37","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/s0885-3924(02)00393-7","volume":"23","author":"RA Desmond","year":"2002","unstructured":"Desmond RA, Weiss HL, Arani RB, Soong SJ, Wood MJ, Fiddian PA, et al. Clinical applications for change-point analysis of herpes zoster pain. J Pain Symptom Manag. 2002;23(6):510\u20136. https:\/\/doi.org\/10.1016\/s0885-3924(02)00393-7.","journal-title":"J Pain Symptom Manag"},{"issue":"1","key":"1355_CR38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1471-2288-5-14","volume":"5","author":"GH Lyman","year":"2005","unstructured":"Lyman GH, Kuderer NM. The strengths and limitations of meta-analyses based on aggregate data. BMC Med Res Methodol. 2005;5(1):14. https:\/\/doi.org\/10.1186\/1471-2288-5-14.","journal-title":"BMC Med Res Methodol"},{"issue":"9","key":"1355_CR39","doi-asserted-by":"publisher","first-page":"MR000007","DOI":"10.1002\/14651858.MR000007.pub3","volume":"9","author":"C Tudur Smith","year":"2016","unstructured":"Tudur Smith C, Marcucci M, Nolan SJ, Iorio A, Sudell M, Riley R, et al. Individual participant data meta-analyses compared with meta-analyses based on aggregate data. Cochrane Database Syst Rev. 2016;9(9):MR000007. https:\/\/doi.org\/10.1002\/14651858.MR000007.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"15","key":"1355_CR40","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.vaccine.2014.01.058","volume":"32","author":"K Kawai","year":"2014","unstructured":"Kawai K, Preaud E, Baron-Papillon F, Largeron N, Acosta CJ. Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review. Vaccine. 2014;32(15):1645\u201353. https:\/\/doi.org\/10.1016\/j.vaccine.2014.01.058.","journal-title":"Vaccine"},{"issue":"2","key":"1355_CR41","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.vaccine.2018.11.056","volume":"37","author":"AJ Leidner","year":"2019","unstructured":"Leidner AJ, Murthy N, Chesson HW, Biggerstaff M, Stoecker C, Harris AM, et al. Cost-effectiveness of adult vaccinations: a systematic review. Vaccine. 2019;37(2):226\u201334. https:\/\/doi.org\/10.1016\/j.vaccine.2018.11.056.","journal-title":"Vaccine"},{"issue":"2","key":"1355_CR42","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40273-018-0735-1","volume":"37","author":"ET Chiyaka","year":"2019","unstructured":"Chiyaka ET, Nghiem VT, Zhang L, Deshpande A, Mullen PD, Le P. Cost-effectiveness of herpes zoster vaccination: a systematic review. Pharmacoeconomics. 2019;37(2):169\u2013200. https:\/\/doi.org\/10.1007\/s40273-018-0735-1.","journal-title":"Pharmacoeconomics"},{"key":"1355_CR43","doi-asserted-by":"publisher","first-page":"101923","DOI":"10.1016\/j.pmedr.2022.101923","volume":"29","author":"NR Meredith","year":"2022","unstructured":"Meredith NR, Armstrong EP. Cost-effectiveness of herpes zoster vaccines in the US: a systematic review. Prev Med Rep. 2022;29:101923. https:\/\/doi.org\/10.1016\/j.pmedr.2022.101923.","journal-title":"Prev Med Rep"},{"issue":"1","key":"1355_CR44","doi-asserted-by":"publisher","first-page":"2168952","DOI":"10.1080\/21645515.2023.2168952","volume":"19","author":"N Giannelos","year":"2023","unstructured":"Giannelos N, Ng C, Curran D. Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: an updated critical review. Hum Vaccin Immunother. 2023;19(1):2168952. https:\/\/doi.org\/10.1080\/21645515.2023.2168952.","journal-title":"Hum Vaccin Immunother"},{"issue":"49","key":"1355_CR45","doi-asserted-by":"publisher","first-page":"8326","DOI":"10.1016\/j.vaccine.2007.09.066","volume":"25","author":"JM Pellissier","year":"2007","unstructured":"Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007;25(49):8326\u201337. https:\/\/doi.org\/10.1016\/j.vaccine.2007.09.066.","journal-title":"Vaccine"},{"issue":"9","key":"1355_CR46","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1111\/j.1532-5415.2010.03021.x","volume":"58","author":"KE Schmader","year":"2010","unstructured":"Schmader KE, Johnson GR, Saddier P, Ciarleglio M, Wang WW, Zhang JH, et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc. 2010;58(9):1634\u201341. https:\/\/doi.org\/10.1111\/j.1532-5415.2010.03021.x.","journal-title":"J Am Geriatr Soc"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01355-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-024-01355-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01355-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T05:35:25Z","timestamp":1715405725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-024-01355-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1355"],"URL":"https:\/\/doi.org\/10.1007\/s40261-024-01355-1","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]},"assertion":[{"value":"3 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GlaxoSmithKline Biologicals SA funded this study (GSK study identifier: VEO-000509) and was involved in all stages of the study conduct, including analysis of the data. GlaxoSmithKline Biologicals SA also took charge of all costs associated with the development and publication of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Nikolaos Giannelos, Bernard Francq, and Desmond Curran are employed by and hold shares in GSK. The authors declare no other financial and non-financial relationships and activities.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors confirm that the data supporting the findings of this study are available within the article and its supplementary information.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Shingrix is a trademark owned by or licensed to GSK. Zostavax is a trademark of Merck Sharp & Dohme Corp. AS01 is a trademark owned by or licensed to GSK.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trademarks"}}]}}